GOLDSTEIN DOV A MD 4

What Happened

• Dov A. Goldstein, MD, Chief Financial Officer of BioAge Labs (BIOA), exercised stock options to acquire 3,542 shares on April 23, 2026. The exercise price was $4.38 per share, for a cash outlay of $15,514. The filing also shows a matching derivative disposition for 3,542 shares at $0.00; the filing does not report any open‑market sale of the shares.

Key Details

• Transaction date: 2026-04-23; Form 4 filed: 2026-04-24 (appears timely).
• Exercise: 3,542 shares acquired at $4.38/share = $15,514 total.
• Matching disposition: 3,542 shares at $0.00 (reported as a derivative disposition; filing does not state proceeds or a sale).
• Shares owned after transaction: Not stated in the provided filing excerpt.
• Footnote: Award vests 1/48th monthly, first tranche vested Feb 1, 2025; subsequent tranches monthly thereafter, subject to continued service.

Context

• This was an option exercise (insider acquiring shares by paying the exercise price), not an open‑market sale. The reported $0.00 derivative disposition does not show a sale for cash; filings like this can reflect conversion, net settlement, or other administrative actions, but this specific Form 4 does not provide further detail.